TransMedics Group, Inc. (TMDX): Price and Financial Metrics

TransMedics Group, Inc. (TMDX): $74.16

1.78 (-2.34%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

D

TMDX Price/Volume Stats

Current price $74.16 52-week high $99.63
Prev. close $75.94 52-week low $36.42
Day low $73.89 Volume 851,900
Day high $77.15 Avg. volume 624,513
50-day MA $84.28 Dividend yield N/A
200-day MA $72.30 Market Cap 2.43B

TMDX Stock Price Chart Interactive Chart >

TMDX POWR Grades

  • Growth is the dimension where TMDX ranks best; there it ranks ahead of 85.45% of US stocks.
  • TMDX's strongest trending metric is Sentiment; it's been moving down over the last 26 weeks.
  • TMDX ranks lowest in Stability; there it ranks in the 0th percentile.

TMDX Stock Summary

  • With a price/sales ratio of 12.74, TRANSMEDICS GROUP INC has a higher such ratio than 91.48% of stocks in our set.
  • With a year-over-year growth in debt of 661.29%, TRANSMEDICS GROUP INC's debt growth rate surpasses 98.51% of about US stocks.
  • Revenue growth over the past 12 months for TRANSMEDICS GROUP INC comes in at 167.34%, a number that bests 96.92% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TRANSMEDICS GROUP INC are FCUV, UUUU, LUCD, ACON, and AREB.
  • Visit TMDX's SEC page to see the company's official filings. To visit the company's web site, go to www.transmedics.com.

TMDX Valuation Summary

  • In comparison to the median Healthcare stock, TMDX's price/sales ratio is 509.09% higher, now standing at 13.4.
  • TMDX's price/sales ratio has moved down 19.7 over the prior 57 months.

Below are key valuation metrics over time for TMDX.

Stock Date P/S P/B P/E EV/EBIT
TMDX 2023-12-29 13.4 20.4 -72.0 -91.8
TMDX 2023-12-28 13.8 20.9 -74.0 -94.2
TMDX 2023-12-27 13.7 20.8 -73.5 -93.6
TMDX 2023-12-26 13.7 20.8 -73.6 -93.7
TMDX 2023-12-22 13.4 20.3 -71.7 -91.4
TMDX 2023-12-21 13.4 20.3 -71.9 -91.6

TMDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TMDX has a Quality Grade of D, ranking ahead of 12.13% of graded US stocks.
  • TMDX's asset turnover comes in at 0.2 -- ranking 143rd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows TMDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.200 0.677 -0.179
2021-03-31 0.162 0.659 -0.164
2020-12-31 0.179 0.649 -0.186
2020-09-30 0.183 0.646 -0.227
2020-06-30 0.202 0.609 -0.280
2020-03-31 0.243 0.610 -0.314

TMDX Price Target

For more insight on analysts targets of TMDX, see our TMDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.00 Average Broker Recommendation 1.5 (Moderate Buy)

TransMedics Group, Inc. (TMDX) Company Bio


TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.


TMDX Latest News Stream


Event/Time News Detail
Loading, please wait...

TMDX Latest Social Stream


Loading social stream, please wait...

View Full TMDX Social Stream

Latest TMDX News From Around the Web

Below are the latest news stories about TRANSMEDICS GROUP INC that investors may wish to consider to help them evaluate TMDX as an investment opportunity.

Fund manager's top growth stock picks for 2024

As 2023 comes to a close, Clough Capital CEO and President Vince Lorusso discusses his top stock picks as we move into the new year. When discussing the funds he manages, Lorusso says, "There's really two different areas of investments. I kind of characterize them as stable growth companies, meaning they might be a little bit more defensive if we do have a little bit of a slowdown in the consumer." Lorusso's top picks for stable growth include Service Corporation International (SCI), Rollins, Inc. (ROL), and gold miners and utilities sectors. "In the other part of the portfolio, are these more dynamic growth companies that we think do have more beta potentially and are most exposed to some of the secular and also cyclical enthusiasm we're seeing around things like AI and EVs." Lorusso's...

Yahoo | December 26, 2023

TransMedics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024, at 3:00 p.m. Pacific Standard Time / 6:00 p.m. Eastern Standard Time.

Yahoo | December 18, 2023

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 7, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 9,547 shares of its common stock and an aggregate of 6,175 restricted stock units to 11 employees, each as a material inducement for each employee's entry into employment with TransMedics. Th

Yahoo | December 12, 2023

Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money

Here are three stocks to buy that could double your money. If Wall Street is right, Madrigal Pharmaceuticals (NASDAQ: MDGL) stock could go a long way toward doubling your money over the next 12 months. Madrigal could win U.S. Food and Drug Administration (FDA) approval for resmetirom in treating nonalcoholic steatohepatitis (NASH) by March 14, 2024.

Yahoo | November 30, 2023

Investing in These 3 Stocks Now Could Make You a Millionaire Retiree

Let me be clear upfront. To have a decent chance of retiring with $1 million or more, you're going to need cash to invest and plenty of time. Exactly how much cash and how much time is required will vary.

Yahoo | November 25, 2023

Read More 'TMDX' Stories Here

TMDX Price Returns

1-mo -17.54%
3-mo -3.98%
6-mo 29.97%
1-year -1.17%
3-year 67.44%
5-year N/A
YTD -6.04%
2023 27.88%
2022 222.13%
2021 -3.72%
2020 4.68%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!